Human Peptide Hormone
Active Substance: Semaglutide GLP-1 RA
Manufacturer: Kalpa Pharmaceuticals
Unit: 2 mL Vial (5 mg/vial)
Semaglutixyl is also known as Semaglutide, Rybelsus, Ozempic.
Semaglutixyl, a pioneering product by Kalpa Pharmaceuticals, contains the active ingredient Semaglutide, which is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). This medication comes in a powder form in 2 mL vials, designed to be reconstituted and used for managing diabetes and contributing to weight management.
Each vial of Semaglutixyl contains 5 mg of Semaglutide. The powder formulation is intended for injection after reconstitution, providing a controlled release of the medication to enhance its efficacy and duration of action.
While Semaglutixyl is not traditionally used for bodybuilding, its effects on weight management and improved metabolic profile can be beneficial for athletes looking to maintain a lean physique. Its ability to reduce appetite and enhance fat loss can indirectly support bodybuilding diet and weight management goals.
Semaglutixyl is primarily indicated for the treatment of type 2 diabetes. It enhances the body's natural ability to control blood sugar levels by increasing insulin secretion. Additionally, it is used for weight loss in patients who may benefit from reduced appetite and calorie intake.
For diabetes management, the starting dose is typically low to assess tolerance, gradually increasing to an effective maintenance dose. Doses vary depending on individual needs and doctor's prescription.
The dosage for women is similar to men, with adjustments made based on medical advice, efficacy, and tolerability of the drug.
Semaglutide maintains an active effect for approximately one week, which supports once-weekly dosing, enhancing compliance and ease of use.
Possible side effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and constipation. More serious risks involve potential thyroid tumors, including cancer. Users should monitor any symptoms closely and consult with healthcare providers.
Semaglutixyl should not be used by individuals with a personal or family history of medullary thyroid carcinoma or those who have Multiple Endocrine Neoplasia syndrome type 2. It is also contraindicated in patients with a known hypersensitivity to Semaglutide.
An overdose of Semaglutixyl may lead to severe nausea, vomiting, and hypoglycemic reactions. Immediate medical attention should be sought if overdose is suspected.
For bodybuilders or athletes, Semaglutixyl might be used in a stack with other supplements for enhanced fat loss and metabolic support. For example, it could be combined with a fat burner like L-Carnitine and a strict dietary regimen to maximize fat loss while preserving muscle mass.
Semaglutixyl is packaged in 2 mL vials containing 5 mg of Semaglutide in a lyophilized powder, ensuring stability and purity of the product.
Store in a refrigerator (2°C to 8°C/36°F to 46°F). Do not freeze. Protect from light. Use within a specified time after reconstitution as recommended by the manufacturer.
Kalpa Pharmaceuticals' Semaglutixyl represents a significant advancement in diabetes management and weight loss therapy, offering a new hope for patients seeking effective control of their symptoms with the convenience of less frequent dosing.
Human Peptide Hormone
Active Substance: Semaglutide
Manufacturer: Dragon Pharma
Unit: 2 mL Vial (5 mg/mL)
Form: Powder
Laboratory Tested: 2024-06-17
Human Peptide Hormone
Active Substance: Semaglutide
Manufacturer: Novo Nordisk
Unit: 1 Pre-Filled Pen (1 mg – 4 doses)
Human Peptide Hormone
Active Substance: Semaglutide
Manufacturer: Ultima Pharmaceuticals
Unit: 2 mL Vial (5 mg/vial)